Elsevier

Journal of Infection

Volume 82, Issue 1, January 2021, Pages 159-198
Journal of Infection

Letter to the Editor
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19

https://doi.org/10.1016/j.jinf.2020.05.039Get rights and content

Highlights

  • No specific treatment against SARS-CoV-2 is available after 6 months of COVID-19 worldwide outbreak.

  • Antivirals could decrease the viral load and reduce direct and indirect damages of SARSCoV-2 infection.

  • Ritonavir-bosted lopinavir is effective against SARS-CoV-2 in vitro.

  • Sequential virological and pharmacological monitoring helped to understand the efficacy of ritonavir-boosted lopinavir in a SARS-CoV-2 infected patient.

  • Ritonavir-boosted lopinavir could be proposed as early treatment for SARS-CoV-2 infection.

Keywords

Sars-cov-2
Covid-19
Lopinavir
Protease inhibitor
Virology
pharmacology

Cited by (0)

On behalf of the « COVID SMIT PSL STUDY GROUP »

1

These authors contributed equally to the present work.

View Abstract